ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions
View by Date
Jump to:  View All • a [b] c d e f g h i j k l m n o p q r s t u v w x y z
  • Abstract Number: 1942
    B Cell Depletion By Rituximab in Lymphocyte Subpopulations from Peripheral Blood in Patients with Rheumatoid Arthritis
  • Abstract Number: 1641
    B Cell Depletion with Rituximab in Patients with Rheumatoid Arthritis: Multiplex Bead Array Reveals Kinetics of IgG and IgA Autoantibodies to Citrullinated Antigens
  • Abstract Number: 1122
    B Cell Phenotypic Changes in Anti-Nuclear Antibody Positive Individuals Prior to the Onset of Systemic Autoimmune Rheumatic Disease
  • Abstract Number: 3157
    B Cell Profile As a Biomarker of Disease Segmentation and Flare Prognosis in SLE
  • Abstract Number: 1113
    B Cell Signature Profiling in Systemic Lupus Erythematosus Patients on Belimumab
  • Abstract Number: 1073
    B Cell Subsets Are Epigenetically and Transcriptionally Dysregulated in Systemic Lupus Erythematosus
  • Abstract Number: 1115
    B Cell-Intrinsic Interferon Gamma Signals Promote the Development of Systemic Lupus Erythematosus By Enhancing the Formation of Spontaneous Autoimmune Germinal Centers
  • Abstract Number: 1096
    B Cells Are Prime Producers of Tumor Necrosis Factor Alpha in Rheumatoid Arthritis
  • Abstract Number: 186
    B Flow, a Novel Ultrasound Modality in the Assessment of Synovitis in RA
  • Abstract Number: 2394
    B-Flow Imaging of Synovial Tissue in Osteoarthritis
  • Abstract Number: 183
    B-Mode and Power Doppler Assessment As Predictors for Short and Long-Term Clinical Outcome in Cts Patients with or without Surgical Treatment
  • Abstract Number: 2460
    B10 Cells May be Involved in Controlling Disease Activity in Polyarticular Juvenile Idiopathic Arthritis Patients
  • Abstract Number: 2806
    Bacterial Skin Microbiome in Psoriatic Arthritis – Pilot Data from Psoriatic Plaques on Dry Skin Sites from Patients with Psoriasis (PsC) and Psoriatic Arthritis (PsA)
  • Abstract Number: 1754
    BANK1 Controls the Development of SLE By Modulating TLR7 Signaling and Type I IFN-Induced Translation Initiation Pathway in B Cells
  • Abstract Number: 2L
    Baricitinib Versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to Background Methotrexate Therapy: Results of a Phase 3 Study
  • Abstract Number: 1045
    Baricitinib, Methotrexate, or Baricitinib Plus Methotrexate in Patients with Early Rheumatoid Arthritis Who Had Received Limited or No Treatment with Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Phase 3 Trial Results
  • Abstract Number: 2498
    Barriers to Appointment Compliance and the Effect of Reminder Phone Calls on Lupus Clinic Show Rate in an Underserved Community
  • Abstract Number: 1424
    Barriers to Primary Care Clinician Adherence to Clinical Guidelines for the Management of Low Back Pain: A Systematic Review and Meta-Synthesis of Qualitative Studies
  • Abstract Number: 2723
    Basal STAT5 Signaling Is Elevated in Multiple Peripheral Blood Cell Subsets in Rheumatoid Arthritis and Is Markedly Downregulated By IFN-γ in T Lymphocytes
  • Abstract Number: 551
    Baseline Autoantibodies Preferentially Impact Abatacept Efficacy in Patients with RA Who Are Biologic Naïve: 6-Month Results from a Real-World, International, Prospective Study
  • Abstract Number: 2728
    Baseline Characteristics and Changes in Disease Activity at 12 Months in Patients Treated with Abatacept Versus Other Biologic Disease-Modifying Antirheumatic Drugs in Clinical Practice Setting
  • Abstract Number: 710
    Baseline Characteristics of Early, Delayed, and Non-Responders in a Non-Radiographic Axial Spondyloarthritis Study
  • Abstract Number: 2041
    Baseline Clinical and Laboratory Features of IgG4-Related Disease: Retrospective Japanese Multicenter Study of 333 Cases
  • Abstract Number: 1979
    Baseline Data on Patients Enrolled in a Randomized, Double-Blind Trial of Tocilizumab in Giant Cell Arteritis
  • Abstract Number: 2876
    Baseline Demographic and Disease Characteristics Associated with Response to Golimumab in Patients with Active Nonradiographic Axial Spondyloarthritis
  • Abstract Number: 2882
    Baseline Extent of Damage at the Spine Predicts Radiographic Progression in Korean Patients Using Golimumab for Ankylosing Spondylitis
  • Abstract Number: 2399
    Baseline Fibulin3 Concentrations Are Associated with Incidence of Clinical Knee OA after 30 Months in Overweight and Obese Women
  • Abstract Number: 1072
    Baseline Gene Expression Profiles in 1760 Patients from Two Phase III Trials of BAFF/BLyS Blockade in SLE
  • Abstract Number: 714
    Baseline MRI and CRP As Predictors of Response to Etanercept in the Management of Patients with Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
  • Abstract Number: 39
    Baseline Obesity and Subsequent Weight Loss Are Independently Associated with Cardiovascular Mortality in Established Rheumatoid Arthritis
  • Abstract Number: 2938
    Baseline Predictors of Remission and Low Disease Activity Using Recently Defined International Criteria in a Multi-Center Lupus Registry Cohort
  • Abstract Number: 545
    Baseline Serum Soluble Interleukin–2 Receptor Alpha (sIL–2Rα) Levels Increased as Intervals Decreased from Cohort Entry to Onset of Incident Rheumatoid Arthritis (pre–RA), not Observed in Matched Control (CN) Subjects
  • Abstract Number: 214
    Basic Calcium Phosphate Crystal Interactions with Tenocytes: An in Vitro Model of Calcific Tendinitis
  • Abstract Number: 8
    Bay 11-7085 Induces Glucocorticoid Receptor Activation and Autophagy to Initiate Human Synovial Fibroblast Cell Death
  • Abstract Number: 2309
    Bedtime, Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia: Results of a Phase 2b Randomized, Double-Blind, Placebo-Controlled Study
  • Abstract Number: 743
    Behavior of Complement Levels and Risk of Organ Involvement in SLE Patients
  • Abstract Number: 750
    Belimumab for Systemic Lupus Erythematosus: A Cochrane Systematic Review and Meta-Analysis
  • Abstract Number: 735
    Belimumab Reduces the Frequency of Flares and Prevents Damage Progression in SLE Patients: Experience in a Clinical Practice Setting
  • Abstract Number: 822
    Beneficial Effect of Botulinum Toxin-a on Raynaud’s Phenomenon in Japanese Patients with Systemic Sclerosis: A Prospective, Open-Label Trial
  • Abstract Number: 475
    Benefits of Achieving Comprehensive Disease Control (CDC) in Patients with Rheumatoid Arthritis: Evidence from the Corrona Registry
  • Abstract Number: 325
    Best Performing Definition of Accelerated Knee Osteoarthritis
  • Abstract Number: 1602
    Beta Cells Function and Insulin Resistance during Tocilizumab Treatment in Non-Diabetic RA Patients: Results from a Single-Center Study
  • Abstract Number: 2779
    Better Drug Survival of Non-TNFi Compared to TNFi Biologics after Non-TNFi Failure in RA Patients: A Single Center Experience
  • Abstract Number: 2727
    BI 695501, a Proposed Biosimilar for Adalimumab, Shows Bioequivalence to Adalimumab Reference Products in a Randomized, Double-Blind Phase I Trial in Healthy Subjects
  • Abstract Number: 634
    Big Data International Primary Sjögren Syndrome Registry: Baseline Characterization and Diagnostic Approach in 6047 Patients Fulfilling the 2002 AE Criteria
  • Abstract Number: 3215
    Bim Suppresses the Development of SLE By Limiting Macrophage Inflammatory Responses
  • Abstract Number: 1853
    Binding of a Novel IgG3 VH4-34 Monoclonal Antibody to ssRNA in SLE
  • Abstract Number: 270
    Biologic Agents in Refractory Adult Still’s Disease: Better Response Rates and Acceptable Safety with Anakinra and Tocilizumab
  • Abstract Number: 464
    Biologic Therapy Treatment Complications in the Alberta Aboriginal Population with Rheumatoid Arthritis
  • Abstract Number: 617
    Biological Down-Titration in RA: Patient Profile and Response to Retreatment in Flaring Patients
  • Abstract Number: 582
    Biological Drugs Dose Tapering in Inflammatory Rheumatic Diseases: 2 Year Results at Basurto University Hospital
  • Abstract Number: 3126
    Biomarkers Associated with Hyperintense White Matter Lesions in Systemic Lupus Erythematosus
  • Abstract Number: 720
    Biomarkers in Lupus Nephritis: The Possible Role of Serum Cystatin C, Serum β2-Microglobulin, Urinary α1-Microglobulin and Albuminâ�„Creatinine Ratio
  • Abstract Number: 1964
    Biomarkers in Temporal Artery Biopsies and Sera of Patients with Giant Cell Arteritis
  • Abstract Number: 722
    Biomarkers/Pathways Discovery of Lupus Nephritis By Urine Proteomics
  • Abstract Number: 1868
    BLK Pathway-Associated rs13277113 GA Genotype Is More Frequent in Systemic Lupus Erythematosus Patients and Associated with Low Gene Expression and Increased Flares
  • Abstract Number: 1771
    Blockade of Immune Complex-Mediated Glomerulonephritis By Highly Selective Inhibition of Bruton’s Tyrosine Kinase
  • Abstract Number: 2789
    Blood and Salivary Gland BAFF-Driven B-Cell Hyperactivity in Rituximab Non-Responder Patients with Primary Sjögren’s Syndrome
  • Abstract Number: 1175
    Blood Outgrowth Endothelial Cells Isolated from Systemic Sclerosis Patients Exhibit a Pro-Inflammatory Phenotype
  • Abstract Number: 2982
    Blood Perfusion in Different Skin Areas of Hands in Primary Raynaud’s Phenomenon and Systemic Sclerosis Patients
  • Abstract Number: 1843
    Bloodstream Infections in Systemic Lupus Erythematosus Patients Are Associated with Severe Lupus Flares
  • Abstract Number: 3155
    Bob1 Expression Is Elevated in Rheumatoid Synovium and Its Expression in B Cells Is Required for Development of Collagen-Induced Arthritis
  • Abstract Number: 553
    Body Mass Index Does Not Influence the Efficacy of Abatacept in Patients with RA Who Are Biologic Naïve: 6-Month Results from a Real-World, International, Prospective Study
  • Abstract Number: 1686
    Body Mass Index Is Associated with Hip Arthritis in Patients with Ankylosing Spondylitis
  • Abstract Number: 2238
    Body Mass Index Modulates the Relationship Between Sugar-Sweetened Beverage Intake and Serum Urate Concentration
  • Abstract Number: 202
    Bone Accrual in the Dnase II-Deficient Model of Autoimmunity Requires Sting, As Well As Hematopoietic and Stromal Elements
  • Abstract Number: 1334
    Bone Erosion in Gout: Relationship with Tophus Urate and Soft Tissue Volumes. a Conventional and Dual Energy CT Study
  • Abstract Number: 1774
    Bone Marrow Derived Dendritic Cells Modified By Lentiviral-Mediated RelB shRNA Possess Tolerogenic Phenotype and Functions on Lupus Splenic Lymphocytes
  • Abstract Number: 2800
    Bone Microarchitecture and Bone Strength in Patients with Primary Sjögren’s Syndrome: A Case-Control Study Using HR-pQCT
  • Abstract Number: 358
    Bone Microstructure Assessed By Hrpqct in Subjects with Hyperuricemia without Arthritis
  • Abstract Number: 1019
    Brain Functional Connectivity Differentially Predicts Response to Two Centrally Acting Analgesics in Fibromyalgia
  • Abstract Number: 3255
    Brain White Matter Integrity: A Future Biomarker for Rheumatoid Arthritis Related Fatigue?
  • Abstract Number: 1121
    Breach of B Cell Anergy in New Zealand Black Congenic Mice
  • Abstract Number: 2023
    Breastfeeding, Oral Contraceptive and the Risk of Rheumatoid Arthritis: Results from the Swedish Epidemiological Investigation of RA Study
  • Abstract Number: 2228
    Brief Educational Intervention Improves Gout Patients’ Understanding of Their Disease
  • Abstract Number: 3016
    Bromodomain Inhibitor JQ1 Modulates Smooth Muscle Cell Switching and Ameliorates Chronic Hypoxia/SU5416-Induced Pulmonary Arterial Hypertension in Mice
  • Abstract Number: 3051
    Bronchial Artery Enlargement May Cause Recurring Hemoptysis in Behçet’s Syndrome Patients with Pulmonary Artery Involvement Despite Response to Treatment
  • Abstract Number: 1124
    Bruton’s Tyrosine Kinase Levels Are Increased in B Cells from Patients with Primary Sjögren’s Syndrome
  • Abstract Number: 3052
    Budd-Chiari Syndrome in Behçet’s Disease:a Retrospective Multicenter Study
  • Abstract Number: 1284
    Burden of Illness Associated with Non-Radiographic Axial Spondyloarthritis: A European Real World Database Analysis from the Clinical and Healthcare System Perspective
  • Abstract Number: 1290
    Burden of Rheumatoid Arthritis in the US Elderly Population: Comorbidities, Healthcare Resource Utilization, and Cost
  • Abstract Number: 2164
    Burden of Symptomatic Knee Osteoarthritis in the United States: Impact of Race/Ethnicity, Age and Sex
Jump to:  View All • a [b] c d e f g h i j k l m n o p q r s t u v w x y z
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology